Jumping Biotech Stock: Trevena (NASDAQ: TRVN)

Especially cheap stocks make a trader richer unless the stock has no future. Trevena has been in the stock market for years but couldn’t rise like Moderna or Regeneron. On Thursday TRVN grew not seriously as today. On over 32 million shares the stock pops 19% as no news from the company regarding product development didn’t come.

Less than $2 costing TRVN may become a target for gamblers who see a nice opportunity to cash out all the margins quickly.

Trevena has been in business for a very long time and its stock has a pattern of long term surging growth. Hence, visionary investors may gather around TRVN by contributing long-lasting funds.

Michael Rowels

Weekend Contributor. Writing for business and finance publishers has become his passion over the last decades after he completed a master's degree in Financial Management. Sharing some opinions and forecasts to thousands of readers is a routine job for him but he never promises to invest in one stock.